- Home
- FULT vs IMVT Comparison
FULT vs IMVT Comparison
Compare FULT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULT
- IMVT
- Stock Information
- Founded
- FULT 1882
- IMVT N/A
- Country
- FULT United States
- IMVT United States
- Employees
- FULT N/A
- IMVT N/A
- Industry
- FULT Major Banks
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FULT Finance
- IMVT Health Care
- Exchange
- FULT Nasdaq
- IMVT Nasdaq
- Market Cap
- FULT 3.9B
- IMVT 3.6B
- IPO Year
- FULT N/A
- IMVT N/A
- Fundamental
- Price
- FULT $20.86
- IMVT $23.86
- Analyst Decision
- FULT Hold
- IMVT Strong Buy
- Analyst Count
- FULT 5
- IMVT 11
- Target Price
- FULT $19.20
- IMVT $46.11
- AVG Volume (30 Days)
- FULT 1.6M
- IMVT 1.1M
- Earning Date
- FULT 01-21-2025
- IMVT 02-10-2025
- Dividend Yield
- FULT 3.45%
- IMVT N/A
- EPS Growth
- FULT N/A
- IMVT N/A
- EPS
- FULT 1.58
- IMVT N/A
- Revenue
- FULT $1,083,452,000.00
- IMVT N/A
- Revenue This Year
- FULT N/A
- IMVT N/A
- Revenue Next Year
- FULT $3.80
- IMVT N/A
- P/E Ratio
- FULT $13.19
- IMVT N/A
- Revenue Growth
- FULT 4.83
- IMVT N/A
- 52 Week Low
- FULT $13.87
- IMVT $22.41
- 52 Week High
- FULT $22.49
- IMVT $41.38
- Technical
- Relative Strength Index (RSI)
- FULT 60.65
- IMVT 40.92
- Support Level
- FULT $18.76
- IMVT $22.41
- Resistance Level
- FULT $21.12
- IMVT $25.29
- Average True Range (ATR)
- FULT 0.56
- IMVT 1.25
- MACD
- FULT 0.18
- IMVT 0.03
- Stochastic Oscillator
- FULT 88.98
- IMVT 42.90
About FULT Fulton Financial Corporation
Fulton Financial is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey, and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).